Physician profile
Samantha Joline Fox
NPI 1023673407
$206,754.80
in general payments reported to CMS, 2019-2025
16 companies · $144K in 2025
The $144K reported for 2025 was more than what 99% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $71.16 · 2023: $1,100 · 2024: $62K · 2025: $144K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $92K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $51K · Travel and Lodging: $30K · Consulting Fee: $23K · Food and Beverage: $11K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $92,375.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $50,500.00 |
| Travel and Lodging | $29,909.16 |
| Consulting Fee | $23,000.00 |
| Food and Beverage | $10,899.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $138,247.09 | 2023-2025 | Auvelity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $26,514.42 | 2023-2025 | Caplyta |
| Supernus Pharmaceuticals, INC. | $24,177.24 | 2024-2025 | Qelbree |
| Abbvie INC. | $15,780.13 | 2023-2025 | |
| Vanda Pharmaceuticals INC. | $505.20 | 2024-2025 | Fanapt, Hetlioz |
| Alkermes, INC. | $390.48 | 2024-2025 | Lybalvi, Aristada |
| Corium, LLC | $373.48 | 2022-2024 | Azstarys |
| E.R. Squibb & Sons, L.L.C. | $190.07 | 2025 | Cobenfy |
| Janssen Pharmaceuticals, INC | $142.48 | 2024-2025 | Spravato |
| Neuronetics, INC. | $120.65 | 2025 | Neurostar Tms Therapy System |
| Neurocrine Biosciences, INC. | $116.10 | 2024-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $114.43 | 2024-2025 | Abilify Asimtufii, Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $23.14 | 2025 | Trintellix |
| Idorsia Pharmaceuticals US INC | $20.77 | 2025 | Quviviq |
| Ironshore Pharmaceuticals INC. | $19.71 | 2023 | Jornay Pm |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $19.41 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samantha Fox listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.